Document Detail


Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss.
MedLine Citation:
PMID:  19968915     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent reports suggest that bone loss begins during late perimenopause at a dramatic rate, even before estrogen levels plummet. During the ensuing 5 years, there is evidence of the beginnings of microarchitectural deterioration, which impacts bone strength and ultimately enhances its propensity to fracture. The diagnosis of osteoporosis based on T-scores alone, or through stratification for a high fracture risk by FRAX, excludes these women who are rapidly losing bone. Because all antiosteoporosis therapies, in particular bisphosphonates, reduce bone loss, we propose aggressive, likely short-term therapy with a goal to reduce bone loss, stabilize bone density, and prevent microarchitectural deterioration.
Authors:
Mone Zaidi; Charles H Turner; Ernesto Canalis; Roberto Pacifici; Li Sun; Jameel Iqbal; X Edward Guo; Stuart Silverman; Solomon Epstein; Clifford J Rosen
Related Documents :
11194525 - Nutrition in bone health revisited: a story beyond calcium.
18987295 - Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse eff...
8845585 - Bisphosphonates and the treatment of bone disease in the elderly.
9706225 - The genetics of osteoporosis: vitamin d receptor polymorphisms.
12417165 - Facial reconstruction using the visor scalp flap.
8676735 - One-stage treatment of infected bone defects of the tibia with skin loss by free vascul...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current osteoporosis reports     Volume:  7     ISSN:  1544-2241     ISO Abbreviation:  Curr Osteoporos Rep     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-12-08     Completed Date:  2010-02-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101176492     Medline TA:  Curr Osteoporos Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  118-26     Citation Subset:  IM    
Affiliation:
The Mount Sinai Bone Program, Box 1055, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA. mone.zaidi@mssm.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bone Density
Bone Density Conservation Agents / therapeutic use
Bone Remodeling
Female
Fractures, Spontaneous / etiology,  prevention & control
Humans
Osteoporosis, Postmenopausal / diagnosis*,  drug therapy*,  physiopathology
Perimenopause
Risk Assessment
Chemical
Reg. No./Substance:
0/Bone Density Conservation Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Osteoporosis prevention and nutrition.
Next Document:  Variation in risk factors for fractures at different sites.